Trouble Viewing This Email: Click Here

October 26, 2021


Summary Graphic

BioTalk Welcomes Mr. Hakdo Kim, President, Korea SMEs & Startups Agency KOSME)

Mr. Hakdo Kim, President, Korea SMEs & Startups Agency KOSME), joins Rich Bendis from the BHI Offices to discuss their biotech mission, their relationship with Maryland, and opportunities to expand in the United States

Listen now on Apple, Google, Spotify, and TuneIn

Read More

Dr. Kim and the delegation for KOSME visit BHI

On September 20th,  BioHealth Innovation, Inc. (BHI) hosted a delegation from KOSME, the Korea SMEs and Startups Agency.  Leading the overseas team was KOSME’s President, Dr. Hakdo Kim, who met with BHI board members, Entrepreneurs in Residence, and recorded a “BioTalk with Rich Bendis” podcast episode in which Dr. Kim discussed a new partnership with BHI and a Memorandum of Understanding KOSME signed with the State of Maryland.  

Read More

Life Sciences Business Strategist - Open Position! Apply Now

BioHealth Innovation (BHI) is an innovation intermediary that facilitates the commercialization of emerging technologies in the BioHealth Capital Region (Maryland, DC and Virginia).

BHI is seeking a Life Sciences Business Strategist to join its team in Rockville, Maryland. This position provides the opportunity to leverage scientific knowledge to evaluate the commercial potential of emerging technologies and provide recommendations on go-to-market strategies.

This is a customer facing role with a focus on supporting clients in the development of commercial analyses and federal grant proposals.

Click here for more details.

Read More

New EMPWR Fund of Fund launched with BioHealth Capital Fund in it

Andrea Alms, Co-Fund Manager & Partner, BioHealth Capital Fund, recently joined a panel on “Impact Firms Take the Lead: Private Equity & Private Credit” with Emerge Capital Management on October 11th. Emerge’s EMPWR Program has a talented roster of sub-advisors that features a special focus on women private fund leaders. During this special webinar panel, we will be focusing on EMPWR’s private equity and private debt sleeve. We will have three private fund managers join us and present how their private, impact funds can improve the quality of life around the world.

Click here to watch the recording.

Read More

SoftSpotTM by PediaMetrix becomes the first smartphone app to receive FDA clearance for cranial measurements

OCT 06, 2025 08:30 EST

PediaMetrix received 510(k) clearance from the US Food and Drug Administration (FDA) for SoftSpotTM, a cross platform software solution for infant cranial evaluation at the point of care. The FDA clearance demonstrates SoftSpot’s safety and efficacy for infant cranial measurements using a smartphone.

“This is an important milestone for PediaMetrix and we see great potential in now bringing this innovative technology to pediatricians in the US and around the world”, said Fereshteh Aalamifar, PhD, President & CEO of PediaMetrix. Currently, pediatricians are not equipped with any tool for quantitative measurement of cranial shape and only perform visual assessment. They refer parents of children at risk to specialists for quantitative measurements, which can cause delays in the early detection and intervention. SoftSpot brings the power of a specialist to a pediatric office using a smartphone.

Read More

BHI EIR Feedback Day October 27th. Register Now!

Are you a biohealth start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? Schedule your feedback session with BHI EIRs on one of the following dates. Pre-registration is required; Sign up here

For questions/more information, contact BHI.

Read More

BHI Board Member Alexandria Venture Investments Maintains Recognition as #1 Most Active Early-Stage Life Science Investor

PASADENA, Calif., Oct. 18, 2021 /PRNewswire/ -- Alexandria Venture Investments, the strategic venture capital platform of Alexandria Real Estate Equities, Inc. (NYSE:ARE), an urban office REIT and the first, longest-tenured and pioneering owner, operator and developer uniquely focused on collaborative life science, agtech and technology campuses in AAA innovation cluster locations, was recognized by Silicon Valley Bank in its Healthcare Investments and Exits: Mid-Year 2021 Report as the #1 most active biopharma corporate investor by new deal volume from 2020 to 1H21 for the fourth consecutive year and the #1 most active new Series A investor in biopharma by new deal volume from 2020 to 1H21. These most recent leadership rankings are a testament to Alexandria's position at the vanguard and heart of the life science ecosystem. In addition to its leadership in early-stage life science venture capital investing, Alexandria Venture Investments was listed as one of the five most active U.S. investors in agrifoodtech in the 2021 AgFunder AgriFoodTech Investment Report earlier this year. Alexandria Venture Investments has for more than 25 years strategically invested in some of the most disruptive life science, agrifoodtech and technology companies advancing transformative new modalities and platforms to meaningfully improve human health. Fully integrated into Alexandria's differentiated and multifaceted business, the highly successful mission-critical Alexandria Venture Investments platform provides the company with strategic insight into these industries, strengthens relationships with key entrepreneurs and investors and enables the curation of the highest-quality tenant base.

Read More

A US – UK Discussion: How to Conduct Clinical Trials as Seth Toback, Vice President, Clinical Development at Novavax and Divya Chadha Manek, Director of Business Development at the National Institute for Health Research (NIHR) join Rich Bendis on BioTalk.

Listen now via Apple, Google, Spotify, and TuneIn

Divya Chadha Manek was appointed as the NIHR CRN’s Head of Commercial Business Development in 2015 then in 2020, Divya was seconded to the UK Vaccines Taskforce (VTF) which was set up in response to the COVID-19 pandemic to lead the UK’s search for a safe and effective vaccine. Divya was responsible for supporting global pharmaceutical companies to rapidly generate the evidence required for marketing authorisation of COVID-19 vaccines. Divya also played a pivotal role in conceptualising and developing the NHS Vaccine Research Registry.

Read More

935 Prose - The Next Evolution of Innovaiton

935 Prose is a 10-story trophy-class, state-of-the-art research/lab building that marries iconic design, and superior lab functionality. It is positioned to recruit and retain the best-and-brightest scientific talent and will set a new standard for life science facilities.

Click here for the brochure

Read More

Phlow Included in BARDA Contract Development and Manufacturing Organization Network to Provide Domestic API Capability for Essential Medicines and Medical Countermeasures

Phlow is strategically working with the U.S. government to ensure preparedness for future national health crises  

October 20, 2021 09:00 AM Eastern Daylight Time

RICHMOND, Va.--(BUSINESS WIRE)--Phlow Corp., a U.S.-based essential medicines impact company, today announced that it has been approved for inclusion in the Biomedical Advanced Research and Development Authority (BARDA) contract development and manufacturing organization (CDMO) network. The network is part of a comprehensive effort by the U.S. government to provide a domestically integrated, systematic approach to the development of the necessary vaccines, drugs, therapies, and diagnostic tools to address public health emergencies.  

Read More

Gain Therapeutics - Gain Therapeutics Appoints Matthias Alder as Chief Operating Officer

BETHESDA, Md., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced the appointment of Matthias Alder as Chief Operating Officer to advance the Company’s strategic and operational objectives, including the establishment of additional industry partnerships and the transition of the Company’s lead program in Gaucher and Parkinson’s Disease into clinical trials, which is expected to occur in 2022.

“I am delighted to welcome Matthias to Gain’s growing team as we methodically scale our platform and build our internal clinical trial capabilities and operations,” said Eric Richman, Chief Executive Officer of Gain. “He brings extensive experience in the pharma and biotech industries and is a seasoned executive who will complement our current executive team at a pivotal time for Gain as we grow the organization and prepare to advance our lead program into clinical trials.”

Read More

Milken Institute Report Highlights How Maryland is Growing one of the Nation’s Strongest Life Science Ecosystems · BioBuzz

Home to an array of renowned universities, federal labs, and government resources, it’s no surprise that the globally renowned Milken Institute found that Maryland “has one of the nation’s strongest life sciences industries,” according to its recent report.

It’s clear that Maryland’s efforts to grow its recognition as a life sciences/biotech hub have paid off. However, there is still more work to be done in order for Maryland’s R&D growth trajectory to keep up with other leading hubs such as Massachusetts and North Carolina.


Read More

FORBES Magazine Insert - Maryland: A Magnet For Innovation by State of Maryland - issuu

This Forbes special section showcases how the state continues to step up its game to keep businesses thriving. Maryland's dynamic and ever-growing aerospace, cybersecurity, energy, financial services, life sciences, manufacturing, and real estate industries are all showcased throughout the publication.

Read More

America on Edge: Settling for Second Place?

The United States is on edge in ways the nation has rarely experienced throughout its young history. The country’s global leadership is being challenged in a rapidly changing and increasingly competitive world. Meanwhile, the nation’s sustained complacency in dealing with long-festering domestic needs has weakened our institutions from within and placed in grave danger our leadership in the critical fields of science and technology—on which so much of our economy and security is based. America is at a tipping point, in short, and Americans are justifiably unsettled.

Read More

Maryland E-Nnovation Grant Supports Medical Research

October 20, 2021    |   By Deborah Kotz

University of Maryland School of Medicine (UMSOM) Dean E. Albert Reece, MD, PhD, MBA, announced today that UMSOM has been awarded $1.25 million in matching funds from the Maryland E-Nnovation Initiative Fund (MEIF), administered by the Maryland Department of Commerce. The funds, totaling $2.5 million when combined with private philanthropy, will enable the establishment of a new Center for Pathogen Research. They will also enable UMSOM to support research professorships in the Department of Microbiology and Immunology and the Department of Neurology.

The Alicia and Yaya Foundation made a $750,000 philanthropic commitment to establish the Alicia and Yaya Foundation Professorship in Pathogen Research in the Department of Microbiology and Immunology. Matching state funds bring the total to $1.5 million, which will establish an endowed professorship for Matthew Frieman, PhD, associate professor of Microbiology and Immunology at UMSOM. He will also serve as the director of a new Center for Pathogen Research.

Read More

Danae Partners with Materic, Receives Follow-on Investment from Conscious Venture Partners

Danae expands its 3-D Print manufacturing capacity, adds access to unique 3D printing technologies from Materic

October 21, 2021, Baltimore, MD – Danae, Inc., a Baltimore-based 3-D Printing design and manufacturing company, today announced it has partnered with Materic, LLC and received investment from Conscious Venture Partners through their Conscious Venture Fund II.

Located at Baltimore’s 1100 Wicomico, Danae has used this investment to install eight new printers to meet its rapidly growing customer demand. The new machines extend Danae’s capabilities allowing them to manufacture parts using Selective Laser Sintering (SLS) or Stereolithography (SLA) technologies. SLS uses a laser to transform powder into a 3D model whereas SLA uses a laser to cure liquid resin into hardened plastic.

Read More

Home | About BHI | BHI News | Programs | Partners | Contact

Copyright AA(C) BioHealth Innovation 2021
All Rights Reserved.

Viewport Window × × ×